The "aspirinization" of obesity—moving from a niche, high-cost injectable to a mass-market, commoditized oral pill—is exactly what we are witnessing. As of late March 2026, the Indian pharmaceutical market is indeed a battlefield of premium innovation versus generic volume.
Here is how Eli Lilly’s strategy is designed to navigate this "clash of titans."
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
